Results 181 to 190 of about 26,025 (223)

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. [PDF]

Blood Adv
Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gómez R, Egan PC, Fletcher L, Foucar C, Garcia JS, Gilberto L, Gómez de León A, Lancet J, Loh KP, Malcovati L, Marini B, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt G, Brignardello-Petersen R.   +24 more
europepmc   +1 more source

Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series. [PDF]

Front Oncol
Li Q, Ji J, Wu Y.
europepmc   +1 more source

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. [PDF]

Cancers (Basel)
Wendler J, Kasenda B, Lauer EM, Kama K, Isbell LK, Marschner D, Scherer F, Malenica N, Gloggengiesser C, Valk E, Schorb E, Illerhaus G.   +11 more
europepmc   +1 more source

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy. [PDF]

Blood Adv
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD.   +28 more
europepmc   +1 more source

Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia. [PDF]

J Transl Med
Dutta D, Maity A, Gupta SK, Gera P, Jain H, Bagal B, Chatterjee G, Rajpal S, Nayak L, Punatar S, Bandyopadhyay S, Chakraborty A, Chendamarai E, Balasundaram N, Gota V, Khattry N, Sengar M, Mathews V, Hasan SK.   +18 more
europepmc   +1 more source

HASH(0x563d43feb630) [PDF]

, 2017
Blagojevic, S., Petersen, P., Wild, C.
core  

Erratum for the Research Article "Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias" by Y. Nishida <i>et al</i>.

Sci Adv
europepmc   +1 more source

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. [PDF]

Ann Hematol
Fransecky L, Fiedler W, Röllig C, Sauer T, Raffel S, Alsdorf W, Heberling L, Steer B, Huber K, Versteegen T, Spory L, Deckbar D, Reiser L, Bendig S, Bastian L, Bozzetti C, Beder T, Neumann M, Brüggemann M, Gökbuget N, Baldus C.   +20 more
europepmc   +1 more source

The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir. [PDF]

PLoS Pathog
Kim Y, Anderson JL, Tumpach C, Solomon A, Ong J, Tanaka K, Zerbato JM, Tan T, Teh CE, Gray DHD, Arandjelovic P, McMahon J, Meagher N, Price D, Pellegrini M, Roche M, Lewin SR.   +16 more
europepmc   +1 more source

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. [PDF]

Blood Adv
Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej R, Bressel M, Di Iulio J, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA.   +16 more
europepmc   +1 more source